Bellerophon Therapeutics has enrolled the first pulmonary hypertension patient in a Phase 2b clinical trial of its INOpulse nitric oxide delivery system. The trial (NCT03267108) of the blood-vessel-widening device will cover people with pulmonary hypertension associated with interstitial lung disease, or PH-ILD. This includes people with idiopathic pulmonary fibrosis,…
First Patient Enrolls in Phase 2b Trial of INOpulse Nitric Oxide Delivery System
I feel hopeful and am looking forward to completing meaningful goals I’ve set for 2018. I’ve had times in the past when the idea of setting goals seemed ridiculous because of having such a serious condition. I realized that for me, this was part of grieving all that…
There’s a lot of literature out there that highlights strategies and tips for coping with a life-threatening illness diagnosis. The challenge is that most of this literature is written based on various theories from professionals including psychologists, chronic-illness specialists and doctors. This literature is very rarely written from a patient’s…
Since being diagnosed with idiopathic pulmonary fibrosis (IPF) in early 2016, I have tried hard not to be angry or ask the rhetorical “Why me?” questions. This isn’t to say I haven’t had moments of weakness when I am upset about being diagnosed with a life-threatening illness as…
The protein FoxO3 plays a central role in idiopathic pulmonary fibrosis, according to a study reporting that a therapy that scientists are testing for cancer could rein in the protein. One of the hallmarks of IPF is overproduction of cells known as fibroblasts and myofibroblasts that alter the structure of lungs, worsening…
Throughout 2017, Pulmonary Fibrosis News Today reported daily discoveries, therapeutic developments, and events related to pulmonary fibrosis. Here, we review the top 10 most-read articles of 2017, with a brief description of what made them interesting and relevant to PF patients, family members, and caregivers. No. 10 – Esbriet’s Efficacy…
If you have read my previous columns or other columns written by patients with idiopathic pulmonary fibrosis (IPF), you likely are aware that physical and mental fatigue is a major side effect of this disease. In my previous columns, I discussed how difficult it has been transitioning from…
For a patient with a life-threatening illness, there is nothing more difficult than asking others to help them with a task that they were once able to do independently. Having to do this highlights the fact that as a chronic illness progresses, including pulmonary fibrosis (PF), a patient’s physical abilities often regress.
Pulmonary fibrosis (PF) is a progressive and life-threatening disease for which there is no cure. This means that a patient’s ability to function and complete daily tasks will change dramatically. Unfortunately, this may affect their career choice and eventually, it can affect the patient’s ability to work at all.
A cancer drug in clinical development might be used to treat pulmonary fibrosis (PF), or as a starting point to develop better antifibrotic treatments, German researchers suggest. Their study, “FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis,” appeared in the journal EMBO Molecular Medicine. In it,…
